Chito-oligosaccharides (COS), derived from chitosan (CH), are attracting increasing attention as drug delivery carriers due to their biocompatibility, biodegradability, and mucoadhesive properties. Grafting, the process of chemically modifying CH/COS by adding side chains, has been used to improve their drug delivery performance by enhancing their stability, targeted delivery, and controlled release. In this review, we aim to provide an in-depth study on the recent advances in the grafting of CH/COS for multifarious applications. Moreover, the various strategies and techniques used for grafting, including chemical modification, enzymatic modification, and physical modification, are elaborated. The properties of grafted CH/COS, such as stability, solubility, and biocompatibility, were reported. Additionally, the review detailed the various applications of grafted CH/COS in drug delivery, including the delivery of small drug molecule, proteins, and RNA interference therapeutics. Furthermore, the effectiveness of grafted CH/COS in improving the pharmacokinetics and pharmacodynamics of drugs was included. Finally, the challenges and limitations associated with the use of grafted CH/COS for drug delivery and outline directions for future research are addressed. The insights provided in this review will be valuable for researchers and drug development professionals interested in the application of grafted CH/COS for multifarious applications.

Cystic fibrosis (CF), a fatal genetic condition, causes thick, sticky mucus. It also causes pancreatic dysfunction, bacterial infection, and increased salt loss. Currently available treatments can improve the patient's quality of life. Drug delivery aided by nanotechnology has been explored to alter the pharmacokinetics and toxicity of drugs. In this short review, we aim to summarize various conventional formulations and highlight advanced formulations delivered via the pulmonary route for the treatment of CF. There is considerable interest in advanced drug delivery formulations addressing the various challenges posed by CF. Despite their potential to be translated for clinical use, we anticipate that a significant amount of effort may still be required for translation to the clinic.

Self-assembled nanocarrier drug delivery has received profuse attention in the field of diagnosis and treatment of diseases. These carriers have proved that serious life-threatening diseases can be eliminated evidently by virtue of their characteristic design and features. This review is aimed at systematically presenting the research and advances in the field of self-assembled nanocarriers such as polymeric nanoparticles, dendrimers, liposomes, inorganic nanocarriers, solid lipid nanoparticles, polymerosomes, micellar systems, niosomes, and some other nanoparticles. The self-assembled delivery of nanocarriers has been developed in recent years for targeting diseases. Some of the innovative attempts with regard to prolonging drug action, improving bioavailability, avoiding drug resistance, enhancing cellular uptake, and so on have been discussed. The discussion about various delivery systems included the investigation conducted at the preliminary stage, i.e., preclinical trials and assessment of safety. The clinical studies of some of the recently developed self-assembled products are currently at the clinical trial phase or FDA approved.